![tert-Butyl (1S,3S,5S)-3-carbamoyl-2-azabicyclo[3.1.0]hexane-2-carboxylate: Case Study Addressing CEP Certification & REACH Registration Compliance Issues](/themes/simple/img/i-home.png "tert-Butyl (1S,3S,5S)-3-carbamoyl-2-azabicyclo[3.1.0]hexane-2-carboxylate: Case Study Addressing CEP Certification & REACH Registration Compliance Issues")
As a new-type foreign trade service provider driven by technology transformation and dual-wheel foreign trade operations, HiSiaddi has established a "1+2+3+4=1" service system and can supply raw materials from well-known original manufacturers for tert-butyl (1S,3S,5S)-3-carbamoyl-2-azabicyclo[3.1.0]hexane-2-carboxylate. With over a decade of market experience and extensive factory technology transformation partnerships, HiSiaddi boasts profound expertise resolving product compliance challenges. Below is a case study detailing HiSiaddi’s resolution of compliance issues for tert-butyl (1S,3S,5S)-3-carbamoyl-2-azabicyclo[3.1.0]hexane-2-carboxylate.
Please contact HiSiaddi customer service if you require additional consulting on compliance matters for this intermediate.
The client is a top 20 global originator pharmaceutical enterprise headquartered in Basel, Switzerland, with saxagliptin tablets as its flagship original product, fully compliant with EMA, FDA, ICH Q7/Q14 and European Pharmacopoeia standards. It enforces the industry’s most stringent compliance requirements for tert-butyl (1S,3S,5S)-3-carbamoyl-2-azabicyclo[3.1.0]hexane-2-carboxylate (hereinafter referred to as "saxagliptin intermediate"), a key chiral intermediate of saxagliptin: CEP/COS certification, formal REACH registration, full-process GMP audits, genotoxic impurity (GTI) control, electronic batch records (21 CFR Part 11) and complete impurity traceability chains, with annual procurement volume of 180 kg, representing a premium EU originator-grade client.
This marked the client’s first procurement of the intermediate from China. A previously selected CEP-certified factory exhibited incomplete compliance documentation, mismatched certifications, incomplete data and inadequate audit preparation, triggering four critical compliance failures:
1. Incomplete CEP certification coverage: The certificate only covered crude intermediate production, excluding final refining workflows, violating EMA’s requirement for full-process finished product certification.
2. Missing formal REACH registration: Only pre-registration completed without official ECHA registration numbers, SDS safety data sheets or exposure assessment reports, risking customs detention upon EU importation.
3. Non-compliant paper-based GMP documentation violating 21 CFR Part 11: Handwritten paper batch records and test reports lacked electronic signatures and audit trails, fully inconsistent with FDA 21 CFR Part 11 electronic data regulations. GTI testing was absent, with no dedicated test methods, validation datasets or batch test evidence to demonstrate non-detectable GTIs. Impurity traceability chains were fragmented, limited to finished product COAs without raw material impurity transfer data, process impurity removal validation or stability impurity trend analysis.
4. Disconnected end-to-end compliance logic chain: Gaps existed across raw material traceability (missing supplier audit reports), process validation (no three consecutive validation batches), quality control (incomplete impurity profiles), stability testing (no six-month accelerated stability data) and document management (no electronic batch records). EMA auditors would classify the quality system as unreliable and reject market access approval.
The client invested three months coordinating factory rectification with minimal progress, with only 45 days remaining before the audit deadline. Failure to fully resolve compliance gaps would force a costly switch to European and American suppliers with a 60% cost increase. The client urgently commissioned HiSiaddi to deliver full-chain compliance resolution within 45 days and guarantee one-pass EMA pre-review.
HiSiaddi’s compliance specialist team immediately conducted full-dimensional compliance audits of factory certifications, documentation, datasets and on-site facilities, identifying four non-compliance items classified as automatic rejection criteria for EU originator procurement:
1.
Partial CEP certification failing finished product coverage The factory’s existing CEP certificate only covered synthesis up to crude intermediate, excluding final recrystallization, drying and packaging refining stages. EMA explicitly mandates full-process CEP certification covering finished intermediate powder; mismatched certificates disqualify products from audit approval.
2.
3.
REACH pre-registration without official ECHA registration numbers Classified as a Substance of Very High Concern (SVHC) under EU REACH regulation, the intermediate with annual export volume exceeding 100 kg requires formal registration. The factory only completed 2008 pre-registration and could not provide ECHA-issued official registration numbers, CLP-compliant SDS documents, risk assessment reports or exposure control measures, exposing shipments to customs seizure and import bans within the EU.
4.
5.
Paper-based incomplete GMP documentation violating 21 CFR Part 11 Handwritten paper batch records and test reports lacked electronic signatures, audit trails and version control, fully contravening FDA 21 CFR Part 11 electronic data standards. No dedicated validated LC-MS/MS GTI testing workflows existed for the intermediate’s potential genotoxic aza-heterocycle and amide functional groups, with zero batch test data proving non-detectable GTIs. Fragmented impurity traceability only included finished product COAs without raw material impurity transfer records, process impurity removal validation or six-month accelerated stability impurity trend datasets, eliminating the ability to explain impurity origins and control mechanisms to EMA auditors.
6.
7.
Disconnected end-to-end compliance traceability chain with severe audit risks Continuous gaps across the full quality workflow (raw material traceability → process validation → quality control → stability testing → document management) would lead EMA auditors to rule the quality system unreliable and incapable of guaranteeing consistent batch quality, resulting in market access rejection.
8.
HiSiaddi established four dedicated working groups (CEP Certification, REACH Registration, GMP Documentation & On-Site Audit) and formulated a 45-day countdown roadmap prioritizing core certification remediation, documentation supplementation, on-site quality system solidification and mock regulatory pre-reviews, with breakthrough strategies across four modules:
Coordination with the European Directorate for the Quality of Medicines (EDQM): HiSiaddi mediated factory submission of full refining-stage technical documentation, quality specifications, validation datasets, personnel qualification records and equipment validation reports to extend CEP certification coverage to the full crude-to-finished product workflow. Expedited critical validation testing: Three consecutive full refining production validation batches, impurity removal efficiency validation and crystal form stability testing were fast-tracked to generate EP-compliant datasets. Full-scope CEP certificate issuance: A complete EDQM CEP certificate covering all production stages was obtained on Day 18, verifiable via the official EDQM database and fully matching finished product procurement requirements.
Partnership with EU local REACH compliance institutions: HiSiaddi provided product CAS number, molecular structure, purity specifications, impurity profiles, annual export volume and intended use to launch official registration workflows. Full REACH technical dossier compilation: IUCLID technical files, CLP-aligned SDS documents, risk assessment reports, exposure control protocols and safe handling guidance were compiled with authentic format-compliant datasets. Official registration number issuance: Official ECHA registration numbers retrievable via the REACH-IT portal were issued on Day 28, alongside compliant SDS documents and risk assessment reports to satisfy EU customs clearance and client archiving requirements.
Electronic record system transformation: The factory was guided to deploy electronic batch record platforms equipped with audit trails, electronic signature functionality and version control. All production logs, test reports, equipment calibration records and facility maintenance logs were fully digitized to align with 21 CFR Part 11 standards. GTI test method development & validation: Partnered with German TÜV, a leading third-party testing authority, to develop exclusive LC-MS/MS GTI detection workflows fully validated for linearity, precision, accuracy and limit of detection. Three consecutive finished batch GTI test reports confirming non-detectable GTIs were delivered. Closed-loop impurity traceability supplementation: Raw material supplier audit reports, raw material impurity testing data, process impurity transfer & removal validation records and six-month accelerated stability impurity trend datasets were compiled into comprehensive impurity traceability reports clearly delineating impurity origins, control thresholds and mitigation measures for every impurity species.
Consolidated full-process compliance dossiers: A 12-volume English-language regulatory filing integrating CEP certificates, REACH registration numbers, electronic batch records, GTI datasets, impurity traceability reports, stability data, personnel qualifications and equipment validation records was compiled with logically structured traceable datasets formatted to EMA standards. On-site compliance system rectification: HiSiaddi compliance specialists conducted seven days of on-site resident guidance to remediate workshop signage, material segregation, equipment status labeling and cleanroom management, ensuring full alignment between physical facilities and supporting documentation. Mock EMA regulatory pre-review: A simulated audit led by a former EMA lead auditor was conducted on Day 42 to identify minor non-conformities for expedited remediation. Formal successful pre-review submission: On Day 45, the client submitted HiSiaddi’s consolidated full compliance dossier and achieved one-pass EMA pre-review approval with zero corrective action requests.
· CEP: Full-process official CEP certificate verifiable via EDQM public database
· REACH: Official ECHA registration number + compliant SDS documents + full risk assessment reports
· GMP: Electronic batch records fully compliant with 21 CFR Part 11 + validated GTI testing workflows & batch reports + complete end-to-end impurity traceability chains
· Regulatory audit: One-pass EMA pre-review approval with closed-loop comprehensive regulatory dossiers
The client’s Compliance Director commented: "HiSiaddi delivered an unprecedented regulatory breakthrough! Within 45 days, they fully resolved our 3-month stalled CEP, REACH and GMP full-chain compliance challenges, delivering professionally formatted rigorous data and logically closed-loop documentation enabling one-pass EMA pre-review with zero corrective actions. This completely eliminated our concerns regarding Chinese suppliers’ regulatory compliance capabilities, avoided a 60% cost escalation from switching to European vendors, and established robust foundations for stable long-term raw material supply."
Building on successful regulatory remediation, the client locked its full annual 180 kg saxagliptin intermediate procurement volume with HiSiaddi, and entrusted HiSiaddi with compliance service and procurement support for three additional premium heterocyclic intermediates under development. Annual combined procurement and compliance service volume exceeded CHF 5 million, establishing a regulatory-bound deep strategic partnership.
As a critical chiral intermediate for EU originator pharmaceuticals, tert-butyl (1S,3S,5S)-3-carbamoyl-2-azabicyclo[3.1.0]hexane-2-carboxylate imposes far more stringent regulatory requirements than standard intermediates, with five mandatory non-negotiable compliance pillars: full-process CEP certification, formal REACH registration, 21 CFR Part 11 electronic data management, GTI control and end-to-end impurity traceability chains.
Core value delivered through this case:
1. Precise identification of high-risk regulatory red lines: Directly targeting four EMA automatic rejection criteria (incomplete CEP coverage, missing REACH formal registration, paper-based non-compliant GMP records, absent GTI testing data) to eliminate inefficient unfocused remediation workstreams.
2. Efficient cross-stakeholder resource coordination: Mobilization of top-tier resources including EDQM, ECHA, German TÜV and former EMA lead auditors to complete full-chain compliance remediation within 45 days, drastically outperforming the industry’s standard 3–6 month turnaround timeline.
3. Integrated alignment of regulatory compliance and product quality: Beyond supplementary certification documentation, process validation, impurity traceability and on-site facility rectification permanently solidified robust quality systems delivering long-term sustained regulatory compliance.
4. Resolution of core mid-to-high-end client pain points: European originator pharmaceutical enterprises’ top regulatory risk concerns center on audit failures and supply chain interruptions stemming from non-compliant documentation. HiSiaddi delivers professional, rapid and closed-loop regulatory compliance services to fully eliminate these concerns, establishing the firm as the preferred compliance partner for mid-to-high-end clients sourcing Chinese pharmaceutical intermediates.
Please contact HiSiaddi customer service if you require additional consulting on compliance matters for tert-butyl (1S,3S,5S)-3-carbamoyl-2-azabicyclo[3.1.0]hexane-2-carboxylate.
+86-13120989737 
info@hisiaddi.com 
English
